RiboCeine Patent assigned to Max International

Dr. Herbert Nagasawa's RiboCeine Technology Now Fully Patented and Assigned to Max International

Max International is proud to officially announce that RiboCeine, the proprietary technology developed by Dr. Herbert Nagasawa and his team of scientific researchers, is now fully patented by the U.S. Patent Office. As per U.S. law, the patent has been granted to Dr. Nagasawa, who has assigned it to Max International. This means that the exclusive ownership and distribution rights for RiboCeine belong with Max International and our Associates. No other company or individual outside of Max International and our Associates may make, use, offer for sale, or sell products containing RiboCeine.

The acquisition of the patent demonstrates our commitment to developing real health breakthroughs backed by scientific research. The granting of this patent is a recognition of RiboCeine's innovative and unique design. When he learned about the granting of the patent, Co-CEO, Dave Bagley stated, "I have never seen a company more focused on scientific development than Max International. Through Dr. Nagasawa's efforts, the company has created an innovative line of supplements that help to promote a healthy lifestyle."

In August 2014 Max issued a Press Release announcing the granting of the patent. To see the official patent, click this link to the USPTO site.

* * * * * * * *

Independent Studies on Ribose-Cysteine

NOTE: The following links take you away from this page to 3rd party research sites.

1. Saltman A.E.D-Ribose-L-cysteine supplementation enhances wound healing in a rodent model. Am J Surg. 2015, 210, 153-158.

2. Kader, T.; Porteous C.M.; Williams M.A.J.A.; Gieseg, S.P.; McCormick, S.P.A. Ribose-cysteine increases glutathione-based antioxidant status and reduces LDL in human lipoprotein(a) mice. Atherosclerosis. 2014, 237, 725-733.

3. Jurkowska, H.; Uchacz, T.; Roberts, J.; Wrobel, M. Potential therapeutic advantage of ribose-cysteine in the inhibition of astrocytoma cell proliferation. Amino Acids, 2011, 41, 131-139.

4. Heman-Ackah, S.E.; Juhn, S.K.; Huang, T.C.; Wiedmann, T.S. Potential therapeutic advantage of ribose-cysteine in the inhibition of astrocytoma cell proliferation. Otolaryngology-Head and Neck Surgery, 2010,143, 429-434.

5. Oz, H.S.; Chen, T.S.; Nagasawa, H., Comparative efficacies of 2 cysteine prodrugs and a glutathione delivery agent in a colitis model.Translational Research, , 150(2), 122-129., 150(2), 122-129.

6. Lucas Slitt, A.M.; Dominick, P.K.; Roberts, J.C.; Cohen, S.D. Effect of Ribose Cysteine Pretreatment on Hepatic and Renal Acetaminophen Metabolite Formation and Glutathione Depletion. Basic Clin. Pharmacol. Toxicol., 2005, 96 (6), 487-94.

7. Waldron, C.A.; Vannais, D.B.; Ueno A.M. A role for long-lived radicals (LLR) in radiation-induced mutation and persistent chromosomal instability: counteraction by Ascorbate and Ribs but not DMSO. Mutation Research. 2004, 551-255-265.

8. Lenarczyk, M.; Ueno, A.; Vannais, D.B.; Kraemer, S.; Kronenberg, A.; Roberts, J.C.; Tatsumi, K.; Hei, T.K.; Waldron, C.A. The "Pro-drug" RibCys Decreases the Mutagenicity of High-LET Radiation in Cultured Mammalian Cells. Radiation Research, 2003, 160, 579-583.

9. Wilmore, B.H.; Cassidy, P.B.; Warters, R.L.; Roberts, J.C. Thiazolidine Prodrugs as Protective Agents against y-Radiation-Induced Toxicity and Mutagenesis in V79 Cells.J. Med. Chem., , 44(16), 2661-2666., 44(16), 2661-2666.

10. Lucus, A.M.; Henning G.; Dominick, P.K.; Whiteley, H.E.; Roberts, J.C.; Cohen, S.D. Ribose Cysteine Protects Against Acetaminophen-Induced Hepatic and Renal Toxicity. Toxicologic Pathology, 2000, 28(5), 697-704.

11. Roberts, J.C.; Phaneuf, H.L.; Dominick, P.K.; Wilmore, B.H.; Cassidy, P.B. Biodistribution of [35S] - Cysteine and Cysteine Prodrugs: Potential Impact on Chemoprotection Strategies. J. Labelled Cpd. Radiopharm., 1999all.riboceine.study1.51

12. Roberts, J.C.; Phaneuf, H.L.; Szakacs, J.G.; Zera, R.T.; Lamb, J.G.; Franklin, M.R. Differential Chemoprotection against Acetaminophen-Induced Hepatotoxicity by Latentiated L-Cysteines. Chem. Res. Toxicol., 1998, 11, 1274-1282.

13. Bantseev, V.; Bhardwaj, R.; Rathbun, W.; Nagasawa, H.T.; Trevithick, J.R. Antioxidants and Cataract: (Cataract Induction in Space Environment and Application to Terrestrial Aging Cataract). Biochem. Mol. Bio. Intl., 1997, 42, 1189-1197.

14. Roberts, J.C.; Koch, K.E.; Detrick, S.R.; Warters, R.L.; Lubec G. Thiazolidine Prodrugs of Cysteamine and Cysteine as Radioprotective Agents. Radiation Research, 1995, 143, 203-213.

15. Carroll, M.P.; Zera, R.T.; Roberts, J.C.; Schlafmann, S.E.; Feeny, D.A.; Johnston, G.R.; West, M.A.; Bubrick, M.P. Efficacy of Radioprotective Agents in Preventing Small and Large Bowel Radiation Injury. Dis. Colon Rectum, 1995, 38(7), 716-722.

16. Roberts, J.C.;Francetic, D.J.; Zera, R.T. Chemoprotection against Cyclophosphamide-Induced Urotoxicity: Comparison of Nine Thiol Protective Agents. AntiCancer Research, 1994, 14, 389-396.

17. Rowe, J.K.; Zera, R.T.; Madoff, R.D.; Fink, A.S.; Roberts, J.C.; Johnston, G.R.; Freeney, D.A.;Young, H.L.; Bubrick, M.P. Protective Effect of RibCys Following High-Dose Irradiation of the Rectosigmoid. Dis. Colon Rectum, 1993, 36(7), 681-687.

18. Roberts, J.C.; Charyulu, R. L.; Zera, R.T.; Nagasawa, H.T. Protection Against Acetaminophen Hepatotoxicity by Ribose-Cysteine (RibCys). Pharmacology & Toxicology, 1992, 70, 281-285.

19. Roberts, J.C.; Francetic, D.J. Mechanisms of Chemoprotection by RibCys, a Thiazolidine Prodrug of L-cysteine. Med. Chem. Res., 1991, 1, 213-219.

20. Roberts, J.C.; Francetic, D.J. Time course for the elevation of glutathione in numerous organs of L1210-bearing CDF1 mice given the L-cysteine prodrug, RibCys. Toxicology Letters, 1991, 59, 245-251.

21. Roberts, J.C.; Francetic, D.J.; Zera, R.T. L-cysteine prodrug protects against cyclophosphamide urotoxicity without compromising therapeutic activity. Cancer Chemotherapy and Pharmacology, 1991, 28, 166-170.

22. Roberts, J.C.; Nagasawa, H.T.; Zera, R.T.; Fricke, R.F.; Goon, D.J. W. Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(polyhydroxyalky)-and 2-(Polyacetoxyalky)-Thiazolidine-4(R)-Carboxylic Acids. Med Chem., 1987, 30, 1891-1896.

Max International LLC Assigned U.S. RiboCeine Patent

Dr. Herbert T Nagasawa, the chemist and scientist who developed the revolutionary compound RiboCeine, has assigned his U.S. patent, #8,501,700, to Max International LLC. Max International, which supplies and distributes a variety of energy and health enhancing products on a global basis, is using RiboCeine in several of its propriety supplement formulas in order to not only assist cells in regaining and maintaining their ATP and GSH levels, but also to hasten the recovery and survival of tissue.

The unique RiboCeine technology developed by Dr. Nagasawa and his research team helps to give important health maintenance and energy recovery qualities to numerous Max International products distributed to countries around the world. RiboCeine was developed as a combination of L-cysteine and D-ribose. Its purpose is to not only speed up the delivery of glutathione (GSH) at the cellular level but also to stimulate the production of adenosine triphosphate (ATP). Thanks to the assignment of the patent for this revolutionary compound to Max International, the company now owns full rights to use RiboCeine in several of its products designed to enhance the user's overall health and immune system response.

25 Years of Research In Glutathione Enhancement

Dr. Nagasawa was inspired to begin researching compounds that could best protect the liver when his own brother returned from the Vietnam War and suffered a variety of health problems due to alcoholism. Nagawasa and his research team eventually discovered that when cells were stimulated to increase their production of glutathione, the liver was better protected from the toxic stress caused by such substances as alcohol. His efforts to help his brother and thousands of other returning war veterans who were doing damage to their livers enabled Dr. Nagasawa to make the amazing discovery that ribose-cysteine, by effectively delivering L-cysteine to cells, would also automatically stimulate the production of glutathione, which in turn serves to protect those same cells from a variety of deadly toxic substances.

RiboCeine patented groundbreaking health enhancing compound

Max International now uses the revolutionary benefits of RiboCeine in some of its most popular health-enhancing products, including MaxATP, MaxOne and Cellgevity. By providing overall support to the immune system by enhancing glutathione delivery and stimulating adenosine triphosphate production, RiboCeine also helps the body detoxify its cells from environmental toxins in addition to neutralizing a variety of free radicals that can lead to more serious health complications, including cancer.

Max International's recent acquisition of the patent for Herbert Nagasawa's revolutionary RiboCeine compound illustrates just how serious this global company's interest is in promoting health enhancing products that are backed by extensive scientific research. Further information about the full line of Max International's innovative supplements can be viewed on our Product Overview page.

Since its founding in 2007, Max International LLC has grown into one of the leading companies supplying high quality health products worldwide based on its results-driven proprietary formulas. Its network of more than 10,000 home-based distributors can be found throughout the United States, Australia, New Zealand, Canada, The Philippines, Singapore, Malaysia, Hong Kong, Ghana, Nigeria, Colombia, and El Salvador.